1334396-29-0

Upstream product

• 846023-24-3 2-cyano-N-(2,4-dichloro-5-methoxyphenyl)acetamide 
• 846023-51-6 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-iodo-6-methoxy-3-quinolinecarbonitrile 
• 846023-38-9 (2E/Z)-2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-2-propenamide 
• 98446-49-2 2,4-dichloro-5-methoxyaniline 

Downstream Products

• 1334396-27-8 C₂₈H₂₉Cl₂N₇O₂ 
• 1334309-46-4 C₂₇H₂₈Cl₂N₈O₂ 
• 1334309-74-8 C₂₇H₂₇Cl₂N₇O₂ 
• 1334310-77-8 C₂₈H₂₉Cl₂N₇O₂ 
• 1334312-08-1 C₂₈H₂₇Cl₂N₇O₂ 
• 1334310-22-3 C₂₉H₂₉Cl₂N₇O₂ 
• 1334310-23-4 C₂₉H₃₁Cl₂N₇O₂ 
• 1334311-68-0 C₂₈H₂₇Cl₂N₇O₂ 
• 1334311-15-7 C₃₀H₃₁Cl₂N₇O₂ 
• 1334396-28-9 C₃₁H₃₃Cl₂N₇O₂ 
• 1334310-24-5 C₂₇H₂₇Cl₂N₇O₂ 
• 1334310-95-0 C₂₆H₂₅Cl₂N₇O₂ 

Relevant academic research and scientific papers

Design, synthesis and pharmacokinetic evaluation of a novel series of triazole-based Src kinase inhibitors with anti-proliferative activity

Src has been recognized as an important therapeutic target for the treatment of cancer. A novel series of triazole-based Src inhibitors were synthesized and evaluated for their anti-proliferative activities in vitro against human lung cancer A549 cells wi